AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28166457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25950588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience task
Number of subjects: 92
Study 25950588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis smoking
Number of subjects: 92
Study 25950588 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 92
Study 23506415 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention (pancreaticojejunostomy or Frey-procedure)
Number of subjects: 88
Study 23506415 — intervention group
Group type: COMPARATOR
Intervention: Optimal current step-up practice (medical treatment followed by endoscopic interventions and surgery if needed)
Number of subjects: 88
Study 23506415 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 88
Study 23506415 — intervention group
Group type: COMPARATOR
Intervention: Optimal current step-up practice
Number of subjects: 88
Study 21621580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse (TM)
Number of subjects: 0
Study 21621580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse plus 900 ppm F (TMP)
Number of subjects: 0
Study 21621580 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro with 950 ppm F
Number of subjects: 0
Study 21621580 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ppm F
Number of subjects: 0
Study 21621580 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm F
Number of subjects: 0
Study 21621580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19508745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for MRKH (CBT-MRKH)
Number of subjects: 0
Study 19508745 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16950026 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation-assisted less invasive total knee arthroplasty (LIS TKA)
Number of subjects: 102
Study 16950026 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty (TKA)
Number of subjects: 102
Study 15477790 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day) for 6 weeks
Number of subjects: 28
Study 15477790 — intervention group
Group type: COMPARATOR
Intervention: Control group (no citalopram)
Number of subjects: 28
Study 11316109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 40
Study 11316109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10789664 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 to 8 mg/d)
Number of subjects: 24335
Study 10789664 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (12.5 to 25 mg/d)
Number of subjects: 24335
Study 8795678 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (nebulised)
Number of subjects: 12
Study 8795678 — intervention group
Group type: COMPARATOR
Intervention: Nebulised saline
Number of subjects: 12
Study 8795678 — intervention group
Group type: COMPARATOR
Intervention: Air (Fio2 0.21)
Number of subjects: 12
Study 8795678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (Fio2 1.0)
Number of subjects: 12
Study 1639990 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona drilling (assisted hatching) in Trial 1
Number of subjects: 330
Study 1639990 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective zona drilling in Trial 2
Number of subjects: 330
Study 1639990 — intervention group
Group type: COMPARATOR
Intervention: Control group in Trial 1
Number of subjects: 330
Study 1639990 — intervention group
Group type: COMPARATOR
Intervention: Control group in Trial 2
Number of subjects: 330
Study 6236286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (as sole antidopaminergic therapy)
Number of subjects: 20
Study 6236286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30282181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal vestibule flap group
Number of subjects: 45
Study 30282181 — intervention group
Group type: COMPARATOR
Intervention: Labial gingival crevicular approach group
Number of subjects: 45
Study 30282181 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 26489704 — intervention group
Group type: COMPARATOR
Intervention: DMARD group (placebo adalimumab)
Number of subjects: 180
Study 26489704 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD+adalimumab group (adalimumab 40 mg/every other week)
Number of subjects: 180
Study 24964689 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management improvement program based on social cognitive theory (SCT), lasting 12 weeks, consisting of 1.5 hours meeting once a week, including group meetings and home visit monitoring.
Number of subjects: 44
Study 24964689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 44
Study 22918099 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush Buddies musical toothbrush
Number of subjects: 120
Study 22918099 — intervention group
Group type: COMPARATOR
Intervention: Colgate Smile toothbrush
Number of subjects: 120
Study 19841966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg initially, then two 5 mg/kg doses 24 h apart)
Number of subjects: 51
Study 19841966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 51
Study 19841966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 51
Study 17607190 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (Tysabri)
Number of subjects: 0
Study 16185378 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (average final dose 1.6 mg/day)
Number of subjects: 3909
Study 12195170 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Clipping (PC) hearing aid circuit
Number of subjects: 360
Study 12195170 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Limiting (CL) hearing aid circuit
Number of subjects: 360
Study 12195170 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide Dynamic Range Compression (WDRC) hearing aid circuit
Number of subjects: 360
Study 12195170 — intervention group
Group type: COMPARATOR
Intervention: Unaided condition
Number of subjects: 360
Study 12195170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aided condition
Number of subjects: 360
Study 9442171 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 14
Study 8596125 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ng/ml exogenous Plasmodium falciparum antigens
Number of subjects: 122
Study 8596125 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 122
Study 8596125 — intervention group
Group type: COMPARATOR
Intervention: Patients with P. falciparum malaria after 4 weeks of chemotherapy
Number of subjects: 122
Study 2198931 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 24
Study 2198931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30496493 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance training (AET, continuous running)
Number of subjects: 124
Study 30496493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensive interval training (IT, 4×4 method)
Number of subjects: 124
Study 30496493 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT, circle training on 8 devices)
Number of subjects: 124
Study 30496493 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no change in lifestyle)
Number of subjects: 124
Study 29368636 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture with usual care (EA with UC)
Number of subjects: 108
Study 29368636 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 108
Study 26824942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir-Valganciclovir dosing adjusted based on Bayesian prediction model (group B)
Number of subjects: 53
Study 26824942 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir-Valganciclovir according to manufacturer's recommendations (group A)
Number of subjects: 53
Study 24473153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg administered 2 hours before surgery and then every 12 hours for 2 doses
Number of subjects: 56
Study 24473153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsule with same dosage)
Number of subjects: 56
Study 21998121 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 61
Study 21998121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 18783877 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 376
Study 18783877 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 376
Study 18783877 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation in watchful waiting group
Number of subjects: 376
Study 18627504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (n = 37)
Number of subjects: 75
Study 18627504 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (n = 38)
Number of subjects: 75
Study 15991263 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines plus ATP (Atepadene, 90 mg daily for 30 days)
Number of subjects: 157
Study 15991263 — intervention group
Group type: COMPARATOR
Intervention: Guidelines alone (no ATP)
Number of subjects: 157
Study 15991263 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines plus ATP
Number of subjects: 157
Study 12106616 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 5799
Study 12106616 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5799
Study 10504011 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 34
Study 10504011 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 34
Study 8938674 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (lisinopril or enalapril)
Number of subjects: 52
Study 1654706 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13
Study 1654706 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 13
Study 1654706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 13
Study 6961459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at 0.56 g/kg
Number of subjects: 30
Study 6961459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at 0.94 g/kg
Number of subjects: 30
Study 6961459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6961459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (both dosages)
Number of subjects: 30
Study 30690930 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI/aflibercept
Number of subjects: 78
Study 27696520 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pancreas system
Number of subjects: 32
Study 27696520 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 32
Study 26486986 — intervention group
Group type: EXPERIMENTAL
Intervention: VMAT (Volumetric Modulated Arc Therapy)
Number of subjects: 188
Study 26486986 — intervention group
Group type: COMPARATOR
Intervention: 3DCRT (3D Conformal Radiotherapy)
Number of subjects: 188
Study 25632744 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhibai Dihuang Pill (ZBDHP), 6 g each time, twice daily for 90 days
Number of subjects: 80
Study 25632744 — intervention group
Group type: COMPARATOR
Intervention: Control group: Vitamin E (100 mg each time, twice per day) and ATP (40 mg each time, twice per day) for 90 days
Number of subjects: 80
Study 25632744 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhibai Dihuang Pill (ZBDHP)
Number of subjects: 80
Study 22189364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic pulsation therapy (5 treatments over 2 weeks)
Number of subjects: 50
Study 22189364 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 50
Study 20003782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic calf compression (IPC)
Number of subjects: 143
Study 20003782 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight heparin (LMWH)
Number of subjects: 143
Study 20003782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prevention strategy)
Number of subjects: 143
Study 17221296 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance dependence (detoxification)
Number of subjects: 470
Study 17221296 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin use
Number of subjects: 470
Study 17221296 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 470
Study 17221296 — intervention group
Group type: EXPERIMENTAL
Intervention: Past suicide attempt
Number of subjects: 470
Study 17221296 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent homelessness
Number of subjects: 470
Study 17221296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic medical illness
Number of subjects: 470
Study 17221296 — intervention group
Group type: COMPARATOR
Intervention: Receipt of primary care
Number of subjects: 470
Study 15045190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazoton uno (459 mg dry extract of stinging nettle roots)
Number of subjects: 246
Study 15045190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 15045190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazoton uno
Number of subjects: 246
Study 11446046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spiral CT scanning
Number of subjects: 0
Study 11446046 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized population-based studies
Number of subjects: 0
Study 9543646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (two 22 mg transdermal patches)
Number of subjects: 20
Study 9543646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7515168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 0
Study 7515168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferons (in combination with chemotherapy and other immunological agents)
Number of subjects: 0
Study 2660376 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 0
Study 2660376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31909672 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 32
Study 31909672 — intervention group
Group type: COMPARATOR
Intervention: Taste-matched placebo
Number of subjects: 32
Study 29971868 — intervention group
Group type: EXPERIMENTAL
Intervention: STE in lead aVL
Number of subjects: 32
Study 29971868 — intervention group
Group type: COMPARATOR
Intervention: No STE in lead aVL
Number of subjects: 32
Study 27267893 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (3.6 g/day for 6 months)
Number of subjects: 223
Study 27267893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 27267893 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 223
Study 25428632 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy and simultaneous talc poudrage (4g)
Number of subjects: 330
Study 25428632 — intervention group
Group type: COMPARATOR
Intervention: Seldinger chest drain insertion followed by instillation of sterile talc (4g)
Number of subjects: 330
Study 23514638 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA with ketorolac 30 mg
Number of subjects: 60
Study 23514638 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 20492044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hegu-Sanyinjiao Matched Points
Number of subjects: 134
Study 20492044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hegu
Number of subjects: 134
Study 20492044 — intervention group
Group type: EXPERIMENTAL
Intervention: Zusanli
Number of subjects: 134
Study 20492044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 134
Study 18237581 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-fat vegan diet supplemented with soy protein and lifestyle changes
Number of subjects: 93
Study 18237581 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study 15627853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) followed by Well-being Therapy (WBT)
Number of subjects: 20
Study 15627853 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 20
Study 12201354 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 30 mg plus Indapamide 2.5 mg
Number of subjects: 171
Study 12201354 — intervention group
Group type: COMPARATOR
Intervention: Fosinopril 20 mg plus Hydrochlorothiazide 12.5 mg
Number of subjects: 171
Study 9989963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study 7775365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 17
Study 7775365 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 17
Study 2156343 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens 0.625 mg for 21 days plus placebo during the last 10 days of each cycle
Number of subjects: 22
Study 2156343 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens 0.625 mg for 21 days plus medrogestone 5 mg/d for 10 days
Number of subjects: 22
Study 2156343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7030636 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg slow-release metoprolol once daily for 6 weeks
Number of subjects: 50
Study 7030636 — intervention group
Group type: COMPARATOR
Intervention: 200 mg conventional metoprolol once daily for 6 weeks
Number of subjects: 50
Study 31327421 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy for prostate cancer
Number of subjects: 0
Study 31327421 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy
Number of subjects: 0
Study 31327421 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal irradiation of the prostate
Number of subjects: 0
Study 27398706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free total DNA levels in women who developed preeclampsia (3.52; 0.11-25.3)
Number of subjects: 350
Study 27398706 — intervention group
Group type: COMPARATOR
Intervention: Cell-free total DNA levels in controls (3.74; 0.12-21.14)
Number of subjects: 350
Study 27398706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free total DNA levels in African American women (6.15; 0.14-28.73)
Number of subjects: 350
Study 27398706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free total DNA levels in Hispanic women (4.95; 0.20-26.82)
Number of subjects: 350
Study 27398706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free total DNA levels and maternal body mass index (BMI)
Number of subjects: 350
Study 25575262 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic composition (5 days prior and 10 days after surgery)
Number of subjects: 75
Study 25575262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 23716409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-based As testing with household education (HE)
Number of subjects: 452
Study 23716409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-based As testing with household education and local media campaign (HELM)
Number of subjects: 452
Study 23716409 — intervention group
Group type: COMPARATOR
Intervention: Fee-based As testing alone (Control)
Number of subjects: 452
Study 21838506 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the subthalamic nucleus (STN)
Number of subjects: 27
Study 21838506 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the globus pallidus internus (GPi)
Number of subjects: 27
Study 21838506 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa therapy postoperatively
Number of subjects: 27
Study 21838506 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally scaled jaw velocity
Number of subjects: 27
Study 21838506 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning DBS off and on
Number of subjects: 27
Study 19364964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dose-dense (IDD) chemotherapy
Number of subjects: 668
Study 19364964 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin/paclitaxel (control)
Number of subjects: 668
Study 17587070 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (AMOX) 1 g twice daily for 100 days
Number of subjects: 145
Study 17587070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 145
Study 17587070 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AMOX and PBO)
Number of subjects: 145
Study 15125804 — intervention group
Group type: EXPERIMENTAL
Intervention: Favourable social comparison information
Number of subjects: 970
Study 15125804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower personal risk
Number of subjects: 970
Study 15125804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac event vignettes
Number of subjects: 970
Study 15125804 — intervention group
Group type: COMPARATOR
Intervention: Unfavourable social comparison information
Number of subjects: 970
Study 11996472 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 every 3 weeks)
Number of subjects: 30
Study 9882028 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 3 g daily
Number of subjects: 99
Study 7526415 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy group
Number of subjects: 170
Study 7526415 — intervention group
Group type: COMPARATOR
Intervention: Nonbiopsy group
Number of subjects: 170
Study 7526415 — intervention group
Group type: COMPARATOR
Intervention: Biopsy group vs Nonbiopsy group
Number of subjects: 170
Study 2844641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-tryptophan (5OHT) plus placebo
Number of subjects: 8